Oncolytics Biotech Inc.
Oncolytics Biotech develops pharmaceutical products for cancer treatment. Theyre developing pelareorep, an immunotherapeutic agent, in phase 3 trials for breast and pancreatic cancer. They have co-development agreements with Merck KGaA/Pfizer Inc. and Roche Holding AG. The company was founded in 1998 and is headquartered in Calgary, Canada.
Overview
Strengths
- Creates economic value: ROIC of 100.0% against a cost of capital (WACC) of 8.7%, a spread of 91.3 percentage points.
- ROIC of 100.0% beats 93% of its 128 Biotechnology peers (median 0.0%).
- Conservative leverage: net debt is only 0.2x EBITDA.
Weaknesses
- Our discounted cash flow model finds no value to support the current price: free cash flow is negative.
- Shareholder dilution: the share count has grown by 20.8% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
- Small company (enterprise value $44 million): thinner analyst coverage, lower liquidity and wider valuation uncertainty.
Key Financial Data